Andrew Jackson has been executive director and deputy head of global corporate security with Novartis International AG since August 2002. He oversees Novartis’ global anti-counterfeiting programme.
Previously, Jackson worked as a security adviser for Société Générale de Surveillance AG and as an independent security consultant. Prior to moving to the private sector, he spent 13 years with the UK Foreign and Commonwealth Office.
Unmask the Fakes
The fight against counterfeit drug sales comes up against many obstacles.